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Abstract. Minor Histocompatibility (mH) antigens are 
polymorphic endogenously s nthesized products that can 
be recognized by alloreactive T cells in the context of ma- 
jor histocompatibility complex molecules. In transplant 
situations where tissue donor and recipient are matched 
for HLA, mH antigens may trigger strong cellular im- 
mune responses. To gain insight into the polymorphism 
of mH antigens we studied their frequencies in the healthy 
population. Five HLA class I restricted mH antigens 
recognized by distinct cytotoxic T-cell (CTL) clones were 
used in the population genetic analysis consisting of a 
panel (N = 100) of HLA typed target cells. Three mH an- 
tigens showed phenotype frequencies of 69 % or higher, 
this contrasted the frequencies of two other mH antigens 
with 16 and 7% respectively. To gain insight into the 
"functional" polymorphism ofthe T-cell response to mH 
antigens, we analyzed the specificity of CTL clones within 
individuals. Three out of five individuals investigated 
shared a CTL response to one single HLA-A2 restricted 
mH antigen. These results indicate limited allelic 
polymorphism for some mH antigens in the healthy 
population and are suggestive of the existence of im- 
munodominant human mH antigens. 
Introduction 
In the mouse almost 50 minor Histocompatibility (mH) 
antigen genes have been mapped and congenic strains 
have been used to obtain information on polymorphism 
and immunogenecity (for a review see Loveland and 
Simpson 1986; Wettstein 1989). Recently, new aspects 
of the biochemical nature of two classical murine mH an- 
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tigens have become available. Using specific CTL lines 
as in vitro tools, R6tzschke and colleagues (1990a) found 
that, as is true for other T cell recognized antigens uch 
as viral and non-viral proteins (Demotz et al. 1989), the 
mH antigens H-Y and H-4 are naturally processed pro- 
teins, probably ofpeptidic nature (R6tzschke t al. 1990b; 
Falk et al. 1990). 
Unlike the situation in experimental nimal models, 
mH antigens in outbred species, such as humans, are dif- 
ficult to identify and quantitate. To date mainly bone mar- 
row transplant (BMT)-related information is available. 
We and other groups reported that both MHC class I 
restricted cytotoxic T cells (CTL) (Goulmy 1988; Van Els 
et al. 1990; Irle et al. 1985; Pierson and Elkins 1987) and 
MHC class II restricted proliferating T cells (Van Els et 
al. 1990; Reinsmoen et al. 1984) reactive to mH antigens 
are commonly found after HLA-identical BMT. Some of 
these mH antigens appear to be widely expressed on 
various tissues throughout the body, whereas others how 
limited tissue distribution (M. de Bueger, A. Bakker, F. 
van der Woude, J. J. van Rood, E. Goulmy, submitted). 
For BMT, it is especially relevant o know whether the 
number of mH antigens that can trigger a CTL response 
in a given transplant situation is very large, or whether 
the response may be restricted to a few mH antigenic 
determinants. To address this question we studied the 
antihost mH antigen-specific CTL response of five dif- 
ferent bone marrow recipients at the clonal level. Here 
we show that the mH antigens tudied not only differ in 
their immunogenecity but also in their population fre- 
quencies. 
Materials and methods 
Blood samples. Heparinized blood samples were collected from five pa- 
tients before and after HLA identical BMT, from their sibling marrow 
donors, and from HLA-typed unrelated individuals. Peripheral B ood 
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Table 1. Minor H antigen specific CTL cloning. 
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Patient CTL line N. clones mH ag mH ag clone % Population 
designation designation analyzed specificity designation frequency 
I HA-1 N= 7 HA-1 B1, B3 69% 
N= 9 HA-? 
II HA-2 N = 17 HA-2 A1, A2 95 % 
N =20 HA-? 
III HA-3 N=27 HA-3 C1, C2, C3 88 % 
N=20 HA-? 
IV HA-4 N= 8 HA-4 D3 16 % 
N= 10 HA-1 D2 69 % 
N = 11 HA-? 
V HA-5 N= 4 HA-5 E3, E5 7 % 
N= 11 HA-1 E2 69 % 
N = 16 HA-? 
Leukocytes (PBL) were isolated by Ficoll-Isopaque densaty gradient 
centrifugation, washed, and resuspended in RPMI 1640-dimethyl- 
sulphoxide (final concentration 10%) for cryopreservation in liquid 
nitrogen. The HLA class I typings of the patients were as follows: patient 
I: HLA-A2, -B27, -B62; patient II: HLA-A1, -A2, -B7, -B8; patient 
III HLA-A1, -A11, -B8, -Bw60; patient IV: HLA-A2, -A3, -B 18, -B44, 
and patient V: HLA-A2, -A29, -B44, -B49. 
Tissue culture medium. All T-cell cultures were performed in RPMI 
1640 supplemented with antibiotics and 15% human serum. 
Generation ofmH antigen specific CTL lines. Five cytotoxic T-cell lines 
(CTLs), previously designated HA-1 through -5, were isolated from 
PBL obtained from five patients after in vivo sensitization by a bone 
marrow allograft from their HLA-genotypically identical siblings 
(Goulmy 1988). Briefly, 4 x 106 posttransplant PBL from patients were 
stimulated with 4 × 106 30 Gy irradiated patients' pretransplant PBL as 
host-specific mH antigen presenting cells. At day 6, T cells were 
specifically restimulated and propagated as described previously 
(Goulmy 1988). These five CTL lines were highly cytotoxic for host 
but not donor cells and were used as typing reagents for mH antigens 
in population and family studies (Goulmy 1988). 
Establishment ofmH antigen specific CTL clones. The CTL lines were 
suspended at 1.5 cells/mi n a feeder cell mixture and plated at 0.2 
mi/well (i. e., 0.3 cells/well) of 96-well round bottom microtiter plates. 
This feeder cell mixture contained: 1) allogeneic PBL (106 cells/ml 
from two or three randomly selected onors, irradiated with 30 Gy); 
2) patient's pretransplant Epstein-Barr virus transformed B-cell line 
(EBV-LCL; 5× 105 cells/mi irradiated with 50 Gy); 3) 1 ~tg/ml 
leucoagglutinin A (Pharmacia Uppsala, Sweden), and 4) 20 U/mi rI1-2 
(Ortho, Braintree, MA). After 9-10 days 0.1 rnl aliquots from each well 
were transferred into replicate wells and were tested for host-specific 
cytotoxicity against SXCr labeled patient's pretransplant EBV-LCL in a 
standard chromium release assay (Goulmy 1988). 
Expansion of CTL clones. Clones with antihost cytotoxic activity were 
selected and split into eigth or more wells of a 96-well plate in the 
presence of fresh feeder mixture. After seven days of expansion, mH 
antigen-specific cytotoxic activity of the clones was determined against 
a panel of target cells derived from patients, donors, and unrelated in- 
dividuals. This procedure yielded among others; 12 mH antigen-specific 
CTL clones, i. e., clones B1 and B3 from patient I; clones A1 and A2 
derived from patient II; clones C1, C2, and C3 from patient III; clones 
D2 and D3 from patient IV, and clones E2, E3, and E5 from patient 
V (see also Table 1). Large scale expansion (30-60 fold) of these clones 
for extensive panel typing was performed as follows: 1 x 106 CTLs 
were cultured together with 10 ml of the above mentioned feeder cell 
mixture in an upright 75 cm 2 tissue culture flask (angle 45 o) in a total 
volume of 80 ml of medium for five days. Then fresh medium containing 
100 U rI1-2/mi was added for 1-3 more days. 
Cell Mediated Lympholysis (CML) assay. Cell mediated lympholysis 
was measured in vitro by using a standard chromium release assay 
(Goulmy 1988). Briefly, 5 x 10351Cr labeled target cells, either T-lym- 
phoblasts generated by treatment of PBL with 1% phytohemagglntinin 
(PHA) mitogen (Difco, Detroit, MI) for 3 days and expansion on in- 
terleukin 2 (IL-2), or EBV-LCL, were incubated together with varying 
numbers of CTLs so that effector:target ra ios of 10:1 and 1:1 were ob- 
tained. After 4 h at 37 °C the supernatants were harvested for counting 
in a gamma counter (Packard Instruments, Downers Grove, IL). Per- 
centages of specific SlCr release were calculated according to the 
following formula; ER-SR/MR-SR× 100%, in which Experimental, 
Spontaneous and Maximal release (ER, SR, and MR) were respectively 
the isotope release by target cells measured in the presence of effector 
cells (ER), in culture medium alone (SR), and in culture medium contain- 
ing the detergent zaponine (MR). 
T-cell receptor (Tcr) DNA rearrangement analysis. DNA was isolated 
from approximately 1-2 × 107 cells as described by Nicklas and co- 
workers (1987). Ten ~tg of DNA was digested with Eco R1 and Hind 
III enzymes (Boehringer, Mannheim, FRG) according to the manufac- 
turer's instructions. The restriction fragments were size-fractionated in 
a 0.8 % agarose gel and blotted onto nylon membranes (Biotrace; Gelman 
Sciences, Ann Arbor, MI) as described (Maniatis et al. 1982; Miltenburg 
et aI. 1990). Tcrb gene rearrangements were detected with the Bgl II 
C/31 fragment of HPB-/32 (Yoshihai et al. 1984). 
Resu l ts  
Isolation of12 mH antigen reactive CTL clones. F ive  CTL  
bu lk  cu l tures  speci f ic  for  mH ant igens were  obta ined 
(Gou lmy 1988) fo l low ing  rest imulat ion  o f  in v ivo pr imed 
PBLs  f rom f ive pat ients  after HLA ident ica l ,  but  mH an- 
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tigen nonidentical, BMT. These CTL lines were cloned 
by limiting dilution, resulting in the isolation of twelve 
mH antigen-specifc CTL clones with codes A1, A2, B1, 
B3, C1, C2, C3, D2, D3, E2, E3, and E5. These CTL 
clones lysed the bone marrow recipient's, but not the 
donor's, target cells in an effector:target ra io-dependent 
manner, and their reactivity could be blocked by the MHC 
class I-specific monoclonal antibody (mAb) w6/32 (data 
not shown). Analysis of DNA rearrangement patterns in- 
volving the c/31 and c132 regions of the Tcr/3 chain con- 
firmed the monoclonal character of CTLs A1, A2, B1, 
C1, D2, D3, and E5, but not of CTLs D3 and E2 (data 
not shown). The CTLs B2, C2, C3, and E3 were not tested 
for Tcr DNA rearrangement patterns. 
Identification of four clusters of mH antigen specific 
clones restriction by HLA-A2. Since the reactivities of 
nine of the twelve CTLs, i. e., A1, A2, B1, B3, D2, D3, 
E2, E3, and E5, were restricted to HLA-A2, comparison 
of their antigenic specificities in an HLA-A2 positive 
healthy population was carried out (Fig. 1). All the 100 
target cells selected for this purpose expressed the 
cellularly defined HLA-A2.1 molecule, as was assessed 
with an anti HLA-A2.1-specific CTL clone (data not 
shown), except arget cell 64 which expressed a so far 
unidentified HLA-A2 variant molecule. As is summarized 
in Figure 1, the nine CTLs defined four distinct clusters 
ofmH antigen specificities. Each of these specificities was 
identified by at least one of the CTLs which were clonal 
according to the Tcr rearrangement analysis. The 
specificity designated HA-1 for its strong similarity with 
the original CTL line HA-1, was identified by CTL clones 
B 1, B3, D2, and E2 and had a phenotype frequency of 
69%. The second specificity, exhibiting the highest fre- 
quency, designated as HA-2 (95%) for its concordance 
with the original CTL line HA-2, was defined by CTL 
clones A1 and A2 (Fig. 1). The third specificity HA-4 
(16%), derived from the original bulk culture HA-4, was 
characterized byCTL clone D3, and the fourth specificity 
HA-5 (7%), isolated from the original CTL line HA-5, 
was defined by CTL clones E3 and E5. The only target 
cell which was discriminative within these clusters was 
the HLA-A2 variant target cell 64. The HA-2-specific 
CTL clone A1, but not A2, and the HA-l-specific CTL 
clone B3, but not B 1, D2, and E2, reproducibly recogniz- 
ed this target cell. In a separate study analyzing 13 natural- 
ly occurring HLA-A2 variants, another example was 
found showing the same discriminatory reaction pattern 
(unpublished observations). 
Possible allelism for HA-l, HA-4, and HA-5. Different 
phenotypes of HLA-A2 positive cells could be 
distinguished according to the expression of zero, 1, 2, 
or 3 mH antigen specifieities. No panel cells were found 
that expressed mH antigens HA-l, -4, and HA-5 
simultaneously. This observation led us to investigate 
whether these latter specificities could be alleles at a single 
locus using a gene counting method of maximum 
likelihood and a test for Hardy-Weinberg fit (Mattiuz et 
al. 1970; Yasuda and Kimura 1968). Because the p-value 
of 0,026 was less than the minimal evel of significance 
of 5 %, as one expects when comparing observed and ex- 
pected values, we have to reject he hypothesis of allelism. 
However, inspection of the intermediate values did not 
reveal any extreme differences between observed and ex- 
pected phenotypes (Table 2). Hence, these results could 
not settle the question of allelism. 
Indication for immunodominance. An inventory of the mH 
antigen response at the individual level was carried out. 
A series of clones obtained from each of the five patients 
was screened for its reactivity against he mH antigen 
specificities HA-I-HA-5. As mentioned above, the selec- 
tion of the CTL clones was based on its specific recipient 
HA CTL 
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Fig. 1. Pattern of reactivity of the nine mH antigen 
specific HLA-A2 restricted CTL clones A1, A2, B1, 
B3, D2, D3, E2, E3, and E5 against 100 HLA - A2 + ve 
target cells. Clusters of concordant specificities HA-l, 
HA-2, HA-4, and HA-5 are indicated. All target cells 
are lysed by a control HLA-A2-specific alloreactive 
CTL clone (data not shown). 
164 Van Els et al.: Immunogenetics of human minor H antigens 
Table 2. Fit for allelism of HA-l, HA-4, and HA-5. 
Antigenic pair OBS EXP (OBS - EXP) 2 Totals 
EXP 
HA-1 HA-4 12 7.400 2.86 2.86 
HA-1 HA-5 4 3.159 0.22 3.08 
HA- 1 null 53 58.440 0.51 3.59 
HA-4 HA-5 1 0.595 0.28 3.87 
HA-4 null 3 8.004 3.13 6.99 
HA-5 null 2 3.247 0.48 7.47 
HA-5 null 25 19.155 1.78 9.26 
X2=9.256. df=3. p=0.026004. Gene frequencies for HA-l, HA-4, 
and HA-5 are 0.44322, 0.08348, and 0.03564 respectively. 
Table 3. Discordancy between the mH HA-2 and HA-3 antigens. 
HA-3 
+ 
HA-2 
+ 30 5 
- 2 1 
All target cells express both the HLA-A1 and -A2 antigens. Phenotype 
frequencies of the mH antigens HA-2 and HA-3 is 95 %, and 87 %, 
respectively. 
cell lysis. Table 1 shows that besides the expected CTL 
clones pecific for mH antigen HA-1, -4, and -5 and CTL 
clones with as yet unknown mH antigen specificity, a 
number of CTL clones displaying mH antigen 
HA-l-specific reactivity were isolated not only from pa- 
tient I [i. e., clones B1 and B3 (Fig. 1)] but also from pa- 
tients IV [i. e., clone D2 (Fig. 1)] and V [i. e., clone E2 
(Fig. 1)]. This initiatory screening for possible mH an- 
tigenic responses favors the existence of immunodomi- 
nant mH antigens. 
Discordance of HA-2 and HA-3. A fifth mH antigen 
specificity recognized in association with HLA-A1 was 
identified by the CTL clones C1, C2, and C3. This 
specificity which was designated HA-3 because of its con- 
cordance with the original CTL line HA-3, occurred with 
a phenotype frequency of 87 % in the HLA-A1 positive 
population (data not shown). Since the specificities HA-2 
and HA-3 have comparable high phenotype frequencies, 
but occur with different restriction molecules, we in- 
vestigated the coexpression f these mH antigens on target 
cells expressing both HLA-A1 and HLA-A2. As shown 
in Table 3, in seven out of 38 cases a discordance was 
found between the reactivity patterns of the HA-2 and 
HA-3-specific lones, indicating that those mH antigens 
are most likely different mH antigenic entities. 
Discussion 
Here we report on a comprehensive population genetic 
analysis of five HLA class I restricted mH antigens using 
mH antigen-specific CTL clones. These analyses hed 
new light on the current estimations of mH antigen im- 
munogenecity and polymorphism in humans. The latter 
has been thought o be extensive, based on the common 
occurrence ofrejection or graft vs host disease after HLA- 
identical BMT (Thomas et al. 1975; Storb et al. 1983). 
The data shown in this communication are not incompati- 
ble with this notion; however, they indicate amore limited 
mH antigen repertoire which may be regulated by two 
mechanisms. The first is thought o operate at the level 
of mH antigen genes, and the second at the level of the 
CTL response. In support of the first mechanism are the 
phenotype frequencies found for the mH antigens under 
study. Two specificities, namely HA-2 and HA-3, are 
almost ubiquitous, being expressed in 95 % and 87 % of 
the HLA-matched population respectively. Likewise, an 
HLA-B7 restricted mH antigen W1 with a phenotype fre- 
quency as high as 80 % has been described by Pierson and 
Elkins (1987). Thus, high phenotype frequencies for mH 
antigens eem to be common, indicating that, at least for 
several mH antigen loci, the allelic variation is limited. 
On explanation for the high phenotype frequencies as 
found for HA-2 and HA-3, is that these mH antigens may 
be encoded by more than one gene. It has been reported 
for a murine mH antigen that two ' independently 
segregating genes, both of which encode self ligands, are 
responsible for deleting particular Tcr V/3-expressing T 
cells (Tomanari and Fairchild 1991). Another explanation 
could be that the apparently frequent coexpression of 
HLA-restriction molecules, and some mH antigen 
specificities, is a direct result of linkage of mH genes to 
the MHC on chromosome 6. Family studies are currently 
being carried out to investigate this possibility. 
In addition, another frequent mH antigen, HA-1 
(69%), was identified. It has been suggested that this an- 
tigen is a possible allele of two less frequent mH antigens 
HA-4 and HA-5. Similarly in the mouse, many non-H-2 
mH antigen loci have one very frequent allele and a low 
number of other very infrequent alleles (Loveland and 
Simpson 1986; Rammensee and Klein 1983). Investiga- 
tion of possible allelism of HA-l, -4, and -5 failed to reach 
a p-value qual to or greater than 0.05. However, the dif- 
ferences between observed and expected numbers are not 
so extreme. Therefore the numbers of tested individuals 
should be increased to really settle this question. 
Furthermore, our results are suggestive for another 
regulatory level for the "functional" polymorphism of 
mH antigens. Most interestingly, CTLs recognizing one 
single mH specificity, namely HA-l, could be isolated 
from three patients with different genetic backgrounds but 
sharig the HLA-A2 molecule. This particular human mH 
Van Els et al.: Immunogenetics of human minor H antigens 165 
antigen behaves as a potent or maybe even immunodomi- 
nant T-cell antigen. Immunodominance is a mechanism 
that could limit the "functional" polymorphism of mH 
antigens, and has been described for certain mH antigens 
in the mouse (Loveland and Simpson 1986; Wettstein and 
Baily 1982). The evidence that HA- 1 behaves as a possible 
immunodominant mH antigen, however, is only preli- 
minary. Not until we can type for more mH antigens and 
carry out an inventory of mH antigen response in more 
individuals can we conclude that the immune response to 
one mH antigen is dominated by another. Identification 
of the most immunogenic mH antigens would benefit bone 
marrow grafting. Typing for mH antigens with extremely 
high or low frequencies such as HA-2, HA-3, or W1 (Pier- 
son and Elkins 1987), or HA-4 and HA-5 has only limited 
clinical relevance. The mH antigen HA-1 could be a can- 
didate for typing. This antigen demonstrates aninteresting 
population frequency. Besides, it should also be noted that 
the anti-HA-1 CTLs were all derived from patients with 
severe graft-vs-host disease. However, a note of caution 
should be made since recent mouse studies demonstrate 
that the prediction of immunodominance based on in vitro 
CTL studies does not always correlate with the develop- 
ment of GvHD (Korngold and Wettstein 1990). 
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